

VYZULTA. bunod ophthalmic



Quang Nguyen, Gagan Sawhney, and Janet Serle talk about safety and tolerability of VYZULTA

Sponsored by Bausch + Lomb.

VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Why is a drug's discontinuation rate important?

Quang Nguyen: Continuing with prescribed medication is a key challenge for any glaucoma patient, as it is in any chronic disease. Some medications successfully lower the IOP, but patients cannot tolerate the side effects, such as red eyes, burning or stinging. Patients are expected to be on these medications for a long time, but if the side effects are too much for them, they may give up

after just a few weeks. In clinical trials, VYZULTA had a discontinuation rate of less than I percent due to ocular adverse events (1).


How can simplifying the glaucoma treatment regimen make a difference to patients' outcomes?

Gagan Sawhney: One of the reasons why patients' disease progresses is poor compliance. Patients have trouble keeping up with multiple doses and medications. The more times you have to take a medication - and the more medications you have to take - the more potential there is for compliance to reduce. What I love about VYZULTA is that, because of its dual mechanism of action, you have the potential for up to that nine-point reduction, which is often significant enough to keep patients on one drop, once a day. Keeping the dosage regimen simple and efficacy high can help to reduce the risk of disease progression (2,3) and, as we know in glaucoma, every millimeter of mercury matters (4).

"What Hove about VYZULTA is that, because of its dual mechanism of action, you have the potential for up to that ninepoint reduction."

What impact does it have on patient visits? Gagan Sawhney: When patients are compliant, their condition is more likely





"In my opinion, **VYZULTA** addresses challenges physicians and patients encounter with topical IOPlowering therapies." each other. If we can find a way to do this while keeping pressure controlled, it will be a win-win for everybody.

Do you factor in patient tolerability when prescribing IOPlowering medication?

Quang Nguyen: It is very important. In my approach: monotherapy, if I choose a drug and the patient tolerates it well, it is References a factor in their adherence to it.

Gagan Sawhney: Of course! We drop is working, but if the patient is tolerating the eye drop. Fortunately, in my experience VYZULTA is well tolerated, and most of my patients have not experienced hyperemia.

lanet Serle: VYZULTA is a very efficacious agent, which greatly enhances outflow. It has excellent tolerability, as evidenced by the low discontinuation rate of 0.6 percent due to ocular

adverse events in clinical trials. In my opinion, VYZULTA addresses challenges physicians and patients encounter with topical IOP-

lowering therapies.

Quang Nguyan, Gagan Sawhney and Janet Serle are consultants of Bausch + Lomb.

Find out more: https://www.vyzultahcp.com/

- I. VYZULTA Prescribing Information. Bausch & Lomb Incorporated.
- have to consider not only if the eye 2. SC Patel, GL Spaeth, "Compliance in patients prescribed eyedrops for glaucoma," Ophthalmic Surgery, 23, 233 (1995). PMID: 7651690.
 - 3. AL Robin et al., "Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use," Am | Ophthalmol, 144, 533 (2007). PMID: 17686450.
 - MC Leske et al., "Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial," Arch Ophthalmol, 121, 48 (2003). PMID: 12523884.

IMPORTANT SAFETY INFORMATION

- Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
- Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
- Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
- Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
- There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients

- Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
- Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

Click here for full Prescribing Information: https://bit.ly/2ZzZGxr

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

VYZULTA and the V design are trademarks of Bausch & Lomb Incorporated or its affiliates

©2018 Bausch & Lomb Incorporated. All rights reserved – VYZ.0157.USA.20 - Date of preparation: October 2020

https://www.bausch.com/ **BAUSCH+LOMB**